← Back to Search

Outreach Strategies for Cardiovascular Disease

N/A
Waitlist Available
Led By Shivan Mehta, MD, MBA
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial will test 3 approaches to increase lipid screenings among primary care patients at Penn Medicine: bulk ordering, outreach mail, & text reminders+scheduling help. We'll observe the number of completed panels after 3 & 6 months.

Eligible Conditions
  • Cardiovascular Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants that completed a lipid panel
Secondary outcome measures
AVCSD risk score
Number of participants that completed a lipid panel in the follow up period
Patients initiated on statins

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Outreach + Bulk ordering + Text Based Reminders and Scheduling assistanceExperimental Treatment1 Intervention
Participants will receive a standard mailed letter, a signed laboratory slip/order, and text-based outreach. It will provide the patient information on walk-in hours in a partnering lab / or ask the patient to schedule an appointment with one of the listed Penn Labs with instructions on how to do so. Patients with an active MyPennMedicine account will be asked to schedule an appointment via MPM. Other patients will be sent a list with the contact of nearby available labs and opening hours and asked to call to schedule an appointment. Up to 2 reminder text messages with the deadline for the lab order will be sent to patients for which no appointment has been scheduled on MyPennMedicine at 2 weeks intervals. Enrollment in the text messaging platform will be opt-out. All results for lipid panel testing will be routed to the patients' primary care provider
Group II: Outreach + Bulk orderingExperimental Treatment1 Intervention
Participants will receive a standard mailed letter about lipid panel screening signed by Penn Primary Care, similar to birthday letters that are currently sent to some practices. These letters or messages will describe the importance of getting a lipid panel, their eligibility for a lipid panel, and information about fasting implications of getting the test. This letter will be complemented by a lipid panel order on behalf of their primary care provider, with a signed laboratory slip/order for lipid panel screening. Laboratory orders will be generated through bulk ordering in the electronic health records for all patients by a designated practice representative and the primary care provider as the authorizing clinician. Participants in Arm 2 will be asked to take the laboratory order to the laboratory of their choice to complete their test within the next 6 weeks.
Group III: Usual careActive Control1 Intervention
Participants will receive usual care only, and no additional intervention from this study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Outreach + Bulk ordering
2023
N/A
~1000
Outreach + Bulk ordering + Text Based Reminders and Scheduling assistance
2023
N/A
~1000

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
1,991 Previous Clinical Trials
42,874,780 Total Patients Enrolled
Shivan Mehta, MD, MBAPrincipal InvestigatorUniversity of Pennsylvania
3 Previous Clinical Trials
21,935 Total Patients Enrolled

Media Library

Outreach + Bulk ordering Clinical Trial Eligibility Overview. Trial Name: NCT05724615 — N/A
Cardiovascular Disease Research Study Groups: Outreach + Bulk ordering, Outreach + Bulk ordering + Text Based Reminders and Scheduling assistance, Usual care
Cardiovascular Disease Clinical Trial 2023: Outreach + Bulk ordering Highlights & Side Effects. Trial Name: NCT05724615 — N/A
Outreach + Bulk ordering 2023 Treatment Timeline for Medical Study. Trial Name: NCT05724615 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this trial accept individuals of advanced age?

"According to the stated prerequisites, individuals aged between 20 and 75 are eligible applicants for this clinical trial."

Answered by AI

Are there currently any openings for prospective participants?

"Information provided by clinicaltrials.gov specifies that this trial is not currently enrolling any more participants, as it was initially posted on March 1st 2023 and had its most recent update on February 9th 2023. However, there are 499 other trials actively looking for volunteers at the moment."

Answered by AI

Is it possible for me to be enrolled in this clinical experiment?

"This trial is seeking 1000 people, aged between 20 and 75 with atherosclerotic cardiovascular disease. Vital requirements include having a Primary Care Physician listed in the past 3 years, as well as an overdue lipid panel check (with no testing done over the past 5 year or diabetes modifier without any lipids checks for more than 1 year)."

Answered by AI
~571 spots leftby Mar 2025